SGD Pharma has signed an agreement with Italian private equity firm Entangled Capital to acquire Alphial, an Italian producer of tubular vials, ampoules and ready-to-use (RTU) products. The acquisition is expected to strengthen SGD Pharma’s European footprint and reinforce its strategy to expand globally in tubular glass converting.

Headquartered in Italy, Alphial employs more than 220 people across four manufacturing sites and is recognised as a specialist supplier of tubular glass products for the pharmaceutical industry. The acquisition is subject to clearance under Italian foreign direct investment (FDI) regulations.

Olivier Rousseau, chief executive officer of SGD Pharma, said: “We are excited to welcome Alphial to the SGD Pharma family. This acquisition represents a significant milestone in our growth strategy and will enable us to better serve our clients with an expanded portfolio of services and solutions.”

The transaction follows a series of recent investments by SGD Pharma aimed at building resilience and capacity in pharmaceutical packaging. Two years ago, the company launched a joint venture with Corning to establish a new tubing facility near its Vemula site in India, designed to strengthen supply chain security, reduce carbon footprint and improve quality control. That facility is now nearing operational readiness.

By acquiring Alphial, SGD Pharma expects to add complementary capabilities to its existing operations in Europe and Asia. Fabio Invernizzi, general manager of SGD Pharma’s West business unit, said: “We have been investing heavily in the development of tubular glass and RTU over the last years. Together with the SGD Pharma team, I’m truly excited to engage with the Alphial team to make this happen.”

Alphial’s integration into SGD Pharma is expected to enhance manufacturing expertise and provide customers with broader access to high-quality tubular glass packaging solutions. Valerio Marchi, chief executive officer of Alphial, said: “We are really pleased to join the SGD Pharma Group. SGD Pharma will help Alphial grow and improve the quality of its offering and of its industrial performance.”

SGD Pharma confirmed that integration planning will begin once the transaction is closed. The company stated that it is committed to ensuring a smooth transition for employees, customers and partners. With the addition of Alphial’s four Italian facilities, SGD Pharma said it aims to deliver long-term growth and operational excellence while further aligning its offering with the evolving needs of the pharmaceutical industry.